University Hospital of Navarra
If you are the contact person for this centre and you wish to make any changes, please contact us.
Specialist physician in the Internal Medicine Department at the Autoimmune Diseases Unit of the Internal Medicine Service at the University Hospital of Navarra and principal investigator of the Inflammatory and Immune-Mediated Diseases Group at the Navarrabiomed-Public University of Navarra research centre, Institute of Health Research of Navarra
Cancer patients receiving a type of immunotherapy known as Immune Checkpoint Inhibitor (ICI) have a higher risk of serious adverse events, such as aortic aneurysm rupture, interstitial lung disease, myositis and liver failure, according to a study published in PNAS. "Establishing formal contraindications for ICI users seems warranted," concludes the analysis, based on more than 290,000 cases from pharmacovigilance databases of the US Food and Drug Administration and the World Health Organisation.